Evidence map›Paper›PMID 30522477›Full record

ArticleBMC structural biology2018

Comparative analysis of interactions between aryl hydrocarbon receptor ligand binding domain with its ligands: a computational study.

Kumaraswamy Naidu Chitrala, Xiaoming Yang, Prakash Nagarkatti, Mitzi Nagarkatti

Open access · hybridAbstract read
In one paragraph

Article in BMC structural biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Targeting AhR as a Novel Therapeutic Modality against Inflammatory Diseases.International journal of molecular sciences · 2021
    Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kumaraswamy Naidu ChitralaDepartment of Pathology, Microbiology and Immunology, University of South Carolina, School of Medicine, Columbia, SC, 29208, USA.
Xiaoming YangDepartment of Pathology, Microbiology and Immunology, University of South Carolina, School of Medicine, Columbia, SC, 29208, USA.
Prakash NagarkattiDepartment of Pathology, Microbiology and Immunology, University of South Carolina, School of Medicine, Columbia, SC, 29208, USA.
Mitzi NagarkattiDepartment of Pathology, Microbiology and Immunology, University of South Carolina, School of Medicine, Columbia, SC, 29208, USA. Mitzi.Nagarkatti@uscmed.sc.edu.
University of South Carolina · US

Funding

Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ENOS, REILLY, NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
Use of Resveratrol to treat experimental multiple sclerosisP01AT003961 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, PRAKASH S · 2007 to 2018
$14.2M
Epigenetic Mechanisms of T Cell Dysregulation in PTSDR01AI129788 · NIAID · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI · 2017 to 2021
$2.4M
Role of natural indoles in experimental autoimmune encephalomyelitisR01AT006888 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI · 2011 to 2015
$2.0M
AhR ligands in epigenetic dysregulation of T cellsR01AI123947 · NIAID · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI, NAGARKATTI, PRAKASH S · 2017 to 2021
$1.8M
Immunopathological basis of PTSDR01MH094755 · NIMH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, PRAKASH S · 2011 to 2015
$1.7M
Estrogen-T cell InteractionsR01ES019313 · NIEHS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI, NAGARKATTI, PRAKASH S · 2010 to 2014
$1.5M
NCCIH NIH HHS P01 AT003961NCCIH NIH HHS R01 AT006888NIAID NIH HHS R01 AI123947NIAID NIH HHS R01 AI129788NIEHS NIH HHS R01 ES019313NIGMS NIH HHS P20 GM103641NIH HHS P01 AT003961NIH HHS P20 GM103641NIH HHS R01AI123947NIH HHS R01 AI129788NIH HHS R01 AT006888NIH HHS R01ES019313NIH HHS R01MH094755NIMH NIH HHS R01 MH094755
6 · The paper itself

Abstract

backgroundAryl hydrocarbon receptor (AhR) ligands may act as potential carcinogens or anti-tumor agents. Understanding how some of the residues in AhR ligand binding domain (AhRLBD) modulate their interactions with ligands would be useful in assessing their divergent roles including toxic and beneficial effects. To this end, we have analysed the nature of AhRLBD interactions with 2,3,7,8-tetrachlorodibenzo-ρ-dioxin (TCDD), 6-formylindolo[3,2-b]carbazole (FICZ), indole-3-carbinol (I3C) and its degradation product, 3,3'-diindolylmethane (DIM), Resveratrol (RES) and its analogue, Piceatannol (PTL) using molecular modeling approach followed by molecular dynamic simulations.

resultsResults showed that each of the AhR ligands, TCDD, FICZ, I3C, DIM, RES and PTL affect the local and global conformations of AhRLBD.

conclusionThe data presented in this study provide a structural understanding of AhR with its ligands and set the basis for its functions in several pathways and their related diseases.

Indexed as

LigandsAnimalsBinding SitesCarbazolesIndolesMiceMolecular Dynamics SimulationPolychlorinated DibenzodioxinsProtein Structure, TertiaryReceptors, Aryl HydrocarbonResveratrolcarbazoleCarbazolesindole-3-carbinolIndolesLigandsPolychlorinated DibenzodioxinsReceptors, Aryl HydrocarbonResveratrolAryl hydrocarbon receptorDietary compoundsMolecular dynamic simulationsMolecular modelling

Identifiers

PMID30522477
PMCPMC6282305
OpenAlexW2902985455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.